IL161559A0 - Dibenzylamine derivatives and pharmaceutical compositions containing the same - Google Patents

Dibenzylamine derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL161559A0
IL161559A0 IL16155903A IL16155903A IL161559A0 IL 161559 A0 IL161559 A0 IL 161559A0 IL 16155903 A IL16155903 A IL 16155903A IL 16155903 A IL16155903 A IL 16155903A IL 161559 A0 IL161559 A0 IL 161559A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
alkyl group
hydrogen atom
Prior art date
Application number
IL16155903A
Other languages
English (en)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of IL161559A0 publication Critical patent/IL161559A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
IL16155903A 2002-08-30 2003-08-29 Dibenzylamine derivatives and pharmaceutical compositions containing the same IL161559A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002255604 2002-08-30
JP2003107161 2003-04-10
PCT/JP2003/011041 WO2004020393A1 (ja) 2002-08-30 2003-08-29 ジベンジルアミン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
IL161559A0 true IL161559A0 (en) 2004-09-27

Family

ID=31980551

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16155903A IL161559A0 (en) 2002-08-30 2003-08-29 Dibenzylamine derivatives and pharmaceutical compositions containing the same
IL161559A IL161559A (en) 2002-08-30 2004-04-22 Dibenzylamine derivatives and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161559A IL161559A (en) 2002-08-30 2004-04-22 Dibenzylamine derivatives and pharmaceutical compositions containing the same

Country Status (25)

Country Link
US (2) US7332514B2 (xx)
EP (2) EP1533292B1 (xx)
KR (1) KR100634195B1 (xx)
CN (1) CN1289467C (xx)
AT (1) ATE353870T1 (xx)
AU (1) AU2003261826B2 (xx)
BR (1) BR0306208A (xx)
CA (1) CA2464846C (xx)
CY (1) CY1106425T1 (xx)
CZ (1) CZ2004627A3 (xx)
DE (1) DE60311821T2 (xx)
DK (1) DK1533292T3 (xx)
ES (1) ES2277142T3 (xx)
HK (1) HK1077567A1 (xx)
IL (2) IL161559A0 (xx)
MX (1) MXPA04005350A (xx)
NO (1) NO328886B1 (xx)
NZ (1) NZ532494A (xx)
PT (1) PT1533292E (xx)
RU (1) RU2293078C2 (xx)
SI (1) SI1533292T1 (xx)
SK (1) SK2332004A3 (xx)
TR (1) TR200401413T1 (xx)
WO (1) WO2004020393A1 (xx)
ZA (1) ZA200403137B (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
WO2004020393A1 (ja) * 2002-08-30 2004-03-11 Japan Tobacco Inc. ジベンジルアミン化合物及びその医薬用途
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
MXPA06003357A (es) * 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
AU2008201550B2 (en) * 2003-09-26 2011-02-10 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
JP4773969B2 (ja) 2003-10-08 2011-09-14 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP4587685B2 (ja) * 2004-03-23 2010-11-24 セントラル硝子株式会社 ３−ホルミル−５−トリフルオロメチルベンゾニトリル誘導体とその製造方法
US20070208003A1 (en) * 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
MXPA06014716A (es) 2004-06-24 2007-03-12 Lilly Co Eli Compuestos y metodos para el tratamiento de dislipidemia.
BRPI0514133A (pt) * 2004-08-05 2008-05-27 Hoffmann La Roche compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
CN101443006B (zh) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 作为cetp抑制剂的新颖的苄胺衍生物
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20100167986A1 (en) * 2005-09-30 2010-07-01 Amjad Ali Cholesteryl Ester Transfer Protein Inhibitors
JP2009512701A (ja) * 2005-10-19 2009-03-26 メルク エンド カムパニー インコーポレーテッド Ｃｅｔｐ阻害薬
AU2006328328B2 (en) * 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
EP1981342B1 (en) * 2005-12-28 2016-11-30 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
WO2007073934A1 (en) * 2005-12-29 2007-07-05 Novartis Ag Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7572823B2 (en) 2006-02-07 2009-08-11 Hoffmann-La Roche Inc. Heteroaryl carboxamide compounds
EP1983966B1 (en) 2006-02-09 2013-06-26 Merck Sharp & Dohme Corp. Polymer formulations of cetp inhibitors
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
AU2007247385B2 (en) * 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
GB0609268D0 (en) * 2006-05-10 2006-06-21 Novartis Ag Organic compounds
MX2008014291A (es) * 2006-05-11 2008-11-18 Novartis Ag Derivados de bencilamina como inhibidores de cetp.
US8022217B2 (en) 2006-07-31 2011-09-20 Cadila Healthcare Limited Compounds suitable as modulators of HDL
KR100821688B1 (ko) 2006-08-10 2008-04-11 (주)유케이케미팜 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법
US7750019B2 (en) * 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
US7659271B2 (en) * 2007-04-13 2010-02-09 Kowa Company, Ltd. Pyrimidine compound having dibenzylamine structure and medicament comprising the same
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP5319457B2 (ja) * 2008-08-25 2013-10-16 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
EP2383253B1 (en) 2008-11-28 2014-03-19 Kowa Company, Ltd. Method for manufacturing trans-{4-[(alkyl amino) methyl]cyclohexyl} acetic ester
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
BR112014000333A2 (pt) 2011-07-08 2017-02-07 Novartis Ag método de tratamento de aterosclerose em sujeitos com triglicerídeo alto
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
WO2014192903A1 (ja) 2013-05-31 2014-12-04 興和株式会社 ジベンジルアミン構造を有するピリミジン化合物の新規形態
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
BR112019001459A2 (pt) 2016-07-27 2019-05-07 Hartis-Pharma Sa combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) * 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
US4064125A (en) 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
US4473579A (en) * 1982-01-26 1984-09-25 American Cyanamid Company Antiatherosclerotic tetrasubstituted ureas and thioureas
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
CA2189036A1 (en) 1994-04-29 1995-11-09 Roland E. Dolle Halomethyl amides as il-1.beta. protease inhibitors
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5834514A (en) * 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU738134B2 (en) 1997-10-02 2001-09-06 Sankyo Company Limited Amidocarboxylic acid derivatives
EP1068178A1 (en) 1998-03-05 2001-01-17 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS
SE9802209D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
ATE361273T1 (de) 1998-09-25 2007-05-15 Monsanto Co Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
JP2002525350A (ja) 1998-09-25 2002-08-13 モンサント カンパニー コレステロールエステル輸送タンパク質活性阻害に有効な置換されたｎ−脂肪族−ｎ−芳香族第三級ヘテロアルキルアミン
MXPA01011757A (es) 1999-05-17 2002-06-04 Novo Nordisk As Antagonistas / agonistas inversos del glucagon.
UA73307C2 (uk) 1999-08-05 2005-07-15 Куміаі Кемікал Індастрі Ко., Лтд. Похідна карбамату і фунгіцид сільськогосподарського/садівницького призначення
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
KR100621294B1 (ko) * 2002-07-03 2006-09-06 에프. 호프만-라 로슈 아게 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도
WO2004020393A1 (ja) * 2002-08-30 2004-03-11 Japan Tobacco Inc. ジベンジルアミン化合物及びその医薬用途

Also Published As

Publication number Publication date
CN1289467C (zh) 2006-12-13
SK2332004A3 (en) 2004-12-01
ES2277142T3 (es) 2007-07-01
CA2464846A1 (en) 2004-03-11
TR200401413T1 (tr) 2005-06-21
BR0306208A (pt) 2004-10-13
US20080146620A1 (en) 2008-06-19
NO328886B1 (no) 2010-06-07
CY1106425T1 (el) 2011-10-12
CN1617850A (zh) 2005-05-18
KR20040075908A (ko) 2004-08-30
WO2004020393A1 (ja) 2004-03-11
US7332514B2 (en) 2008-02-19
HK1077567A1 (en) 2006-04-13
MXPA04005350A (es) 2004-09-27
DE60311821D1 (de) 2007-03-29
EP1829858A2 (en) 2007-09-05
RU2293078C2 (ru) 2007-02-10
SI1533292T1 (sl) 2007-08-31
CA2464846C (en) 2010-04-06
ATE353870T1 (de) 2007-03-15
EP1533292A1 (en) 2005-05-25
AU2003261826B2 (en) 2006-02-02
DE60311821T2 (de) 2007-10-31
AU2003261826A1 (en) 2004-03-19
US20050059810A1 (en) 2005-03-17
DK1533292T3 (da) 2007-06-04
PT1533292E (pt) 2007-05-31
EP1533292A4 (en) 2005-11-02
NZ532494A (en) 2006-03-31
KR100634195B1 (ko) 2006-10-16
EP1829858A3 (en) 2007-10-03
CZ2004627A3 (cs) 2004-10-13
RU2004119546A (ru) 2005-08-10
ZA200403137B (en) 2005-06-29
IL161559A (en) 2009-12-24
NO20042584L (no) 2004-06-18
EP1533292B1 (en) 2007-02-14
US7807701B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
IL161559A0 (en) Dibenzylamine derivatives and pharmaceutical compositions containing the same
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
ATE254609T1 (de) Aminothiazolderivate, sie enthaltende arzneimittel und zwischenprodukte in der herstellung dieser verbindungen
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
TW200510440A (en) Novel compounds
EA200601235A1 (ru) Производные тиазола
TW200619212A (en) Morpholine derivatives
HUT53099A (en) Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds
HUP0301811A2 (hu) Hipolipidémiás és hipokoleszterinémiás hatású szubsztituált pirrolszármazékok, azokat tartalmazó gyógyszerkészítmények, eljárás elżállításukra, köztitermékek és alkalmazásuk
AU6158486A (en) Dihydro pyridine derivatives
EP1219607A4 (en) INTEGRASE INHIBITORS WITH AN AROMATIC HETEROCYCLUS
WO2010082212A3 (en) N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses
EP1908752A4 (en) NEW 2-CHINOLO DERIVATIVES
HUP0303457A2 (hu) Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk
HRP20050617A2 (en) Imidazol derivatives having affinity for alpha 2 receptors activity
ATE229538T1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
EP0798304A4 (en) DRUGS AGAINST TRHOMBOCYTOPENIA
GB9407637D0 (en) Serotoninergic abeo-ergoline derivatives
HUP0201255A2 (hu) Új pirimidin-4-on-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyászati készítmények
EP1072582A4 (en) INTERMEDIATES IN THE SYNTHESIS OF A RING UNIT OF THE VITAMIN DERIVATIVES SUBSTITUTED IN POSITION 2
EP1151993A4 (en) CYCLIC AMINE DERIVATIVES AND THEIR APPLICATIONS
GEP19960472B (en) Method of producing derivative of quinoline or its pharmaceutically acceptable ester, or their salts